Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
Article 2015 en
Authors
AP
Antonio Palumbo
FG
Francesca Gay
FC
Federica Cavallo
Abstract
1 min read
In this pooled analysis, CT significantly improved PFS1, PFS2, and OS. The improvement in PFS2 suggests that the benefit reported during first remission is not cancelled by a shorter second remission. PFS2 is a valuable end point to estimate long-term clinical benefit and should be included in future trials.
Meletios A Dimopoulos, Andrzej Jakubowiak, Philip L. McCarthy, Robert Z. Orlowski, Michel Attal, Joan Bladé, Hartmut Goldschmidt, Katja Weisel, Karthik Ramasamy, Sonja Zweegman, Andrew Spencer, Jeffrey Huang, Jin Lu, Kazutaka Sunami, Shinsuke Iida, Wee Joo Chng, Sarah A. Holstein, Alberto Rocci, Tomáš Skácel, Richard Labotka, Antonio Palumbo, Kenneth C. Anderson
Wee Joo Chng, Meral Beksaç, Roman Hájek, Katja Weisel, María‐Victoria Mateos, Andrew Spencer, Shinsuke Iida, Danielle de Farias, Richard Labotka, Tomáš Skácel, Antonio Palumbo, Sagar Lonial, Shaji Kumar, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.